Table 1.
Nasal symptoms after LTB4 challenge.
| LTB4 (μg) | Sneezes (0–3) |
Secretion (0–3) |
Blockage (0–3) |
Irritation (0–3) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prior | 1 h | 4 h | Prior | 1 h | 4 h | Prior | 1 h | 4 h | Prior | 1 h | 4 h | |
| 0 (Sham) | 0 (0) | 0 (0) | 0 (0) | 0 (1.0) | 0 (1.0) | 0 (1.0) | 0 (1.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 2.0 | 0 (0) | 0 (0) | 0 (0) | 0 (1.0) | 0 (1.0) | 0 (0) | 0 (1.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 20 | 0 (0) | 0 (0) | 0 (0) | 0 (1.0) | 0 (0) | 0 (1.0) | 0 (1.0) | 0 (0) | 0 (1.0) | 0 (0) | 0 (0) | 0 (0) |
Median levels (interquartile ranges) of symptoms recorded prior to nasal challenge with sham and two doses of LTB4 as well as 1 and 4 h thereafter. LTB4 did not produce any rhinitis symptoms or any nasal irritation. Comparisons are made with sham challenge at each time-point (all statistically non-significant).